MK-2206 + selumetinib

MK-2206 + selumetinib is an investigational oral combination therapy consisting of two small molecule inhibitors targeting key cancer signaling pathways. MK-2206 is an allosteric inhibitor of AKT 1/2/3 (protein kinase B), while selumetinib (also known as AZD6244 or ARRY-142886) is a selective inhibitor of MEK 1/2. The rationale for combining these agents stems from the frequent dysregulation and compensatory activation between the PI3K/AKT/mTOR and RAS/RAF/MEK pathways in various cancers, particularly those with KRAS mutations. By simultaneously inhibiting both AKT and MEK signaling, this combination aims to overcome resistance mechanisms seen with single-agent therapies. Clinical trials have evaluated this regimen primarily in advanced solid tumors such as colorectal cancer and pancreatic cancer[1][4][5][6]. While preclinical data supported synergistic antitumor activity, clinical studies have been limited by overlapping toxicities (notably rash and gastrointestinal effects) that restrict dose escalation; no significant improvement in overall survival was observed compared to standard chemotherapy regimens[3][10].

Other names

selumetinib sulfate/MK-2206MK2206 + AZD6244